Optos posted revenue of around $23m for the three-month period ended December 31, 2007, the Scottish eyecare company said yesterday in its first interim management statement.

Optos posted revenue of around $23m for the three-month period ended December 31, 2007, the Scottish eyecare company said yesterday in its first interim management statement.

The figure met company estimates for the period, Optos told the London Stock Exchange. The firm's eye-testing machines, most of which are sold in the US and Europe, produce a high-resolution image of the retina in a single capture, allowing identification and prevention of eye disease, such as retinal detachment and age-related degeneration, at an early stage.

Under its business model, Optos retains ownership of the expensive P200 machines and charges for each test.

"We are progressing to plan and expect to report results for the first half of the year that are in line with management expectations," said Thomas Butts, Optos chief executive.

He said that revenue growth was driven ahead by strong demand in the primary care market in the United States and Germany.

Optos has found new markets for its devices in a number of countries in mainland Europe. It reported progress in France, Spain, Switzerland and Norway.

The company also said prospects for its new P200MA machine in the medical care market "remain positive". The device will be introduced commercially as planned in the second quarter of the current year.

Optos issued the interim statement to the stock exchange yesterday to meet requirements under UK Listing Authority and Disclosure rules.

The company also said it will issue a trading statement in advance of reporting interim results for the six months ended March 31, 2008.

Optos was founded by electronics designer Douglas Anderson in 1992 to help his then five-year-old son, Leif, who had become blind in one eye after a detached retina was detected too late.

Shares in Optos rose by 0.25p to 116.75p at the close of London dealing.